LoginSignup
Vertex Pharms logo

Vertex Pharms

Stock
Stock
ISIN: US92532F1003
Ticker: VRTX
US92532F1003
VRTX

Price

Price

Frequently asked questions

What is Vertex Pharms's market capitalization?

The market capitalization of Vertex Pharms is $116.20B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Vertex Pharms?

Vertex Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.992. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Vertex Pharms's stock?

Currently, 31 analysts cover Vertex Pharms's stock, with a consensus target price of $468.58. Analyst ratings provide insights into the stock's expected performance.

What is Vertex Pharms's revenue over the trailing twelve months?

Over the trailing twelve months, Vertex Pharms reported a revenue of $10.63B.

What is the EBITDA for Vertex Pharms?

Vertex Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $4.51B. EBITDA measures the company's overall financial performance.

What is the free cash flow of Vertex Pharms?

Vertex Pharms has a free cash flow of -$1.35B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Vertex Pharms's stock?

The 5-year beta for Vertex Pharms is 0.37. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Vertex Pharms have, and what sector and industry does it belong to?

Vertex Pharms employs approximately 5,400 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Vertex Pharms's shares?

The free float of Vertex Pharms is 257.33M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $116.20B

5Y beta

 0.37

EPS (TTM)

 -$1.992

Free Float

 257.33M

Revenue (TTM)

 $10.63B

EBITDA (TTM)

 $4.51B

Free Cashflow (TTM)

 -$1.35B

Pricing

1D span
$445.02$456.53
52W span
$346.29$519.88

Analyst Ratings

The price target is $468.58 and the stock is covered by 31 analysts.

Buy

21

Hold

7

Sell

3

Information

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.

5,400

Biotechnology & Drugs

Health Care

Identifier

ISIN

US92532F1003

Primary Ticker

VRTX

Knockouts

Join the conversation
Sign upLogin